Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why ImmunoGen Shot Up 13% Today

By Brian Orelli, PhD - Dec 26, 2018 at 4:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech jumps on no obvious news.

What happened

Shares of ImmunoGen ( IMGN 30.73% ) jumped 13% on Wednesday on no obvious news, as the biotech remains a play toy for day traders.

So what

ImmunoGen is sitting in limbo right now awaiting data from its phase 3 study, dubbed Forward I, which is testing its lead drug mirvetuximab as a monotherapy in patients with ovarian cancer. With the trial fully enrolled, management expects data from the study in the first half of next year, setting up a potential approval in late 2019 or early 2020.

Valuing a biotech with an upcoming binary event is squishy -- for lack of a better word -- because there are a lot of variables that have to be estimated, including the likelihood of a positive outcome and the price-to-sales multiple investors will eventually assign the company once the drug is on the market. That lack of clarity can result in a wide trading range for the stock price, allowing day traders to jump in and out as momentum changes.

Man extending a bull figurine with a bear figurine in background

Image source: Getty Images.

Now what

Long-term investors can ignore the daily gyrations and focus on the fundamentals, which aren't likely to change until the upcoming data release. Management has indicated that it's started initial planning for a launch, but hasn't invested much, which seems like a prudent move given ImmunoGen's limited resources.

Investors also should be watching the company's earlier-stage pipeline drugs, IMGN 779 and IMGN 632, which treat acute myeloid leukemia, as well as an ongoing study called Forward II that's testing combination treatments with mirvetuximab. If Forward I fails, it'll be a big blow to ImmunoGen, but at least the biotech has a backup plan.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
IMGN
$6.21 (30.73%) $1.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.